XML 72 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies - Contingencies - Additional Information (Detail)
€ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 48 Months Ended
Dec. 31, 2022
USD ($)
Nov. 30, 2022
USD ($)
Nov. 09, 2022
USD ($)
Aug. 05, 2021
USD ($)
Jul. 21, 2021
USD ($)
Sep. 30, 2013
USD ($)
Apr. 30, 2013
USD ($)
Aug. 31, 2012
USD ($)
Dec. 31, 2010
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2017
USD ($)
Aug. 21, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Jul. 08, 2021
USD ($)
Aug. 31, 2019
USD ($)
Jul. 31, 2008
USD ($)
Feb. 28, 2005
USD ($)
Commitment And Contingencies [Line Items]                                            
Damages assessment                   $ 235,500,000                        
Annual sales at the time of settlement                   700,000,000                   $ 350,000,000    
Annual sales of Effexor                                 $ 2,600,000,000          
Annual sales of Lamictal                                         $ 2,300,000 $ 950,000,000
Annual sales of Niaspan           $ 1,100,000,000 $ 416,000,000                              
Annual sales of Actos               $ 2,800,000,000 $ 3,700,000,000                          
Annual sales of Acto plus               $ 430,000,000 $ 500,000,000                          
Litigation settlement amount   $ 4,250,000,000                                        
Annual Sales Of Sensipar                             $ 1,400,000,000              
Litigation settlement amount awarded distribution period   13 years                                        
Annual sales of Copaxone                         $ 373,000,000                  
Generic modafinil, and imposed fines amount $ 4,186,000,000                 4,299,000,000   $ 4,186,000,000           € 60.5        
Loss Contingency Accrual, Provision       $ 235,500,000                                    
Annual sales of the time of settlement of viread                   582,000,000                        
Annual sales of the time of settlement of Truvada                   2,400,000,000                        
Annual sales of the time of settlement of Atripla                   2,900,000,000                        
Annual sales of the time of New launch of viread                               $ 728,000,000            
Annual sales of the time of New launch of Truvada                           $ 2,100,000,000                
Annual sales of the time of New launch of Atripla                           $ 444,000,000                
Annual sales of Colcrys                       $ 187,000,000                    
Litigation Settlement Amount Distributable In Kind   $ 1,200,000,000                                        
Accrual for Environmental Loss Contingencies                   $ 300,000                        
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]                   Liabilities, Current                        
Loss Contingencies On Environmental Laws Penalty                                     $ 1,400,000      
Percentage of the population of the participating states                   98.00%                        
Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement                   99.00%                        
Annual Sales Of Revlimid                   $ 3,500,000,000                        
Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer 300,000,000                                          
Annual Sales Of EpiPen 600,000,000                                          
Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population $ 1,000,000                                          
Percentage Of Share Of The National Population 1.00%                                          
Percentgae of amount in cash settlement   20.00%                                        
Litigation Settlement Amount Distributable in cash   $ 240,000,000                                        
Loss Contingency, Damages Awarded, Value     $ 176,500,000                                      
Four Other Defendants Other Than Teva [Member]                                            
Commitment And Contingencies [Line Items]                                            
Loss contingency payment         $ 26,000,000,000                                  
Nationwide Settlement [Member] | Four Other Defendants Other Than Teva [Member]                                            
Commitment And Contingencies [Line Items]                                            
Litigation settlement amount awarded distribution period         18 years                                  
Europe [Member]                                            
Commitment And Contingencies [Line Items]                                            
Damage claimed                     $ 50,000,000                      
Eosinophilic Esophagitis [Member]                                            
Commitment And Contingencies [Line Items]                                            
Damage claimed                     200,000,000                      
Eosinophilic Esophagitis [Member] | United States [Member]                                            
Commitment And Contingencies [Line Items]                                            
Damage claimed                     $ 150,000,000                      
AndroGel Rate at 1% [Member]                                            
Commitment And Contingencies [Line Items]                                            
Annual sales at the time of settlement                                       $ 140,000,000